MedMira Inc.
TSXV:MIR Stock Report
MedMira Dividends and Buybacks
Dividend criteria checks 0/6 MedMira does not have a record of paying a dividend.
Key information Total Shareholder Yield n/a Future Dividend Yield n/a Dividend Growth n/a Next dividend pay date n/a Ex dividend date n/a Dividend per share n/a Payout ratio n/a
Recent dividend and buyback updates
Show all updates
MedMira Inc. Announces Clinical Trials to Get Underway with Multiplo(R) Complete Sy Diseases (TP/nTP) Antibody Test Aug 14
New major risk - Financial position Jul 08
Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2023) Jul 04
New minor risk - Share price stability Jun 04
New minor risk - Shareholder dilution May 29
Second quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2023) Apr 02
New major risk - Revenue and earnings growth Jan 02
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test Dec 14
MedMira Inc., Annual General Meeting, Feb 09, 2024 Dec 13
Full year 2023 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in FY 2022) Dec 01
Medmira Inc. Provides Update on Its Progress to Achieve Regulatory Approval in Canada and the USA for Its Infectious Disease Rapid Tests Sep 28
Third quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2022) Jul 02
Second quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2022) Apr 08
MedMira Inc., Annual General Meeting, Feb 16, 2023 Jan 05
First quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 1Q 2022) Jan 01
MedMira Inc. Introduces VYRA TriDemic Dec 30
Full year 2022 earnings released: CA$0.003 loss per share (vs CA$0.001 loss in FY 2021) Dec 01
MedMira Inc. Announces Board Changes Jul 15
Third quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2021) Jul 01
MedMira Inc. Provides an Update on the New in Vitro Diagnostic Medical Devices Regulation in the European Market May 28
MedMira Inc. Provides an Update on Regulatory Work for Canada for Its VYRA™ Product Line May 21
Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2021) Apr 02
We Take A Look At Whether MedMira Inc.'s (CVE:MIR) CEO May Be Underpaid Jan 29
First quarter 2022 earnings: Revenues and EPS in line with analyst expectations Jan 02
First quarter 2022 earnings: Revenues and EPS in line with analyst expectations Jan 02
Medmira Inc. Announces VYRA CoV2Flu and Additional Regulatory Opportunities Dec 22
MedMira Inc. announced that it has received CAD 1.665691 million in funding Dec 15
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Dec 03
MedMira Inc. announced that it has received CAD 0.500108 million in funding Jul 15
Third quarter 2021 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2020) Jul 02
MedMira Inc. Announces Performance Update on World Health Organisation SARS-CoV2 Serology Standards Jun 16
Second quarter 2021 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2020) Apr 03
MedMira Inc. Announces Expansion of its Product Portfolio and Outlines the Company’s Covid-19 Market and Regulatory Plan Mar 05
MedMira Inc. Announces Progress Update on its COVID-19 Product Family Jan 31
New 90-day high: CA$0.43 Jan 21
Here's What We Think About MedMira's (CVE:MIR) CEO Pay Jan 20
Medmira Inc. Announces Product Update Jan 01
MedMira Inc. Applies to US FDA to Obtain FDA Emergency Use Authorization for the REVEALCOVID-19TM Total Antibody Test Dec 26
First quarter 2021 earnings released: EPS CA$0.001 Dec 25
New 90-day low: CA$0.23 Dec 22
Full year 2020 earnings released: CA$0.003 loss per share Dec 02
New 90-day low: CA$0.23 Nov 10
MedMira Reports Additional Independent Performance Evaluation Results of REVEALCOVID-19™ Total Antibody Test Oct 08
New 90-day low: CA$0.28 Sep 24
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MIR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MIR's dividend payments have been increasing.
Dividend Yield vs Market MedMira Dividend Yield vs Market
How does MIR dividend yield compare to the market? Segment Dividend Yield Company (MIR) n/a Market Bottom 25% (CA) 1.7% Market Top 25% (CA) 6.1% Industry Average (Medical Equipment) 1.7% Analyst forecast (MIR) (up to 3 years) n/a
Notable Dividend: Unable to evaluate MIR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MIR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate MIR's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MIR has not reported any payouts.
Discover strong dividend paying companies Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}